GET DAILY SIGNALSLUNG vs SRTS: Weighing Two Small-Cap Medical Device Stocks
Key Takeaways
- LUNG (Pulmonx Corporation) and SRTS (Sensus Healthcare) are both small-cap medical device companies, but they operate in different niches: minimally invasive lung treatment versus non-invasive skin cancer therapy.
- Pulmonx recently returned to year-over-year revenue growth and sharply narrowed its losses, reflecting improved commercial execution and cost discipline.
- Sensus Healthcare has posted steep revenue declines in recent quarters but carries a meaningful catalyst in new reimbursement (CPT) codes for superficial radiation therapy.
- Tickeron AI Verdict: Based on trend consistency, scale, and stability, the AI currently favors LUNG over SRTS, though both names carry elevated small-cap risk.
- For more detail, explore LUNG Major News, LUNG Today's Price Move, SRTS Major News, and SRTS Today's Price Move.
- To see how automated systems are trading these and other tickers, visit the Trending AI Robots page.
Why These Two Names Often Appear Together
Investors screening small-cap medical device names often encounter LUNG and SRTS together because both are development-stage, unprofitable healthcare companies competing for attention in the same broad sector. Despite superficial similarities, the two businesses differ sharply in their treatment technologies, revenue scale, and near-term momentum. This stock comparison is most relevant to growth-oriented traders and investors who are comfortable with elevated volatility and who want to weigh relative performance, catalysts, and market positioning before forming a view on either name. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Pulmonx and Its Recent Momentum
Pulmonx Corporation (LUNG) is a commercial-stage medical technology company focused on minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its flagship Zephyr Endobronchial Valve is designed to improve breathing without major surgery, supported by the Chartis pulmonary assessment system and the LungTraX imaging platform.
In recent weeks, Pulmonx's quarterly results signaled a return to top-line growth in both its U.S. and international businesses, while its net loss narrowed by roughly 40% year over year. Management has reiterated full-year revenue guidance and highlighted cost-reduction initiatives that are improving operating leverage. A leadership transition, including the return of a prior chief executive, has been a focal point for sentiment, with analysts maintaining a broadly constructive view even as price targets have been recalibrated. Relative to the broader market, the stock has lagged in 2026 but has shown pronounced swings in response to earnings and analyst commentary. From what I see, the cost discipline here stands out.
Sensus Healthcare’s Challenges and Catalyst
Sensus Healthcare (SRTS) manufactures and sells superficial radiation therapy (SRT) devices used to treat non-melanoma skin cancers such as basal cell and squamous cell carcinomas, as well as other skin conditions like keloids. Its portfolio includes the SRT-100 systems and a growing software platform, Sensus Link.
Recent market activity for Sensus has been shaped by a difficult transition period. The company's quarterly revenue declined sharply year over year, driven in part by the absence of sales to its historically largest customer and by third-party financing delays that postponed revenue recognition on several high-value systems. At the same time, the company has a notable catalyst: new dedicated CPT (Current Procedural Terminology) reimbursement codes for SRT that took effect at the start of the year, which management credits with improving physician economics and strengthening its commercial pipeline. Analysts have kept a positive rating on the shares, though price targets have been reduced following recent results. I’m watching this closely for signs of stabilization.
Head-to-Head Comparison
From a business-model standpoint, LUNG is further along the commercialization curve, generating significantly more revenue from a global installed base of pulmonology centers. SRTS, by contrast, is smaller in scale and has historically relied on a concentrated customer base, which introduces greater quarter-to-quarter variability in results.
On growth drivers, LUNG's momentum rests on rebuilding its U.S. sales force and expanding international adoption, while SRTS's outlook hinges on converting a strengthened pipeline into revenue under new reimbursement codes. Risk factors differ as well: LUNG faces execution risk tied to a leadership reset and cash burn, whereas SRTS faces customer concentration and the uncertain timing of large system orders. Market sentiment is mixed for both, but LUNG has shown more stable revenue trends and greater trading liquidity, while SRTS trades at a lower market capitalization with higher analyst-implied upside and correspondingly higher volatility.
Tickeron AI Verdict
Weighing trend consistency, revenue stability, scale, and the clarity of near-term catalysts, Tickeron's AI currently leans toward LUNG as the more favorable of the two. Pulmonx's return to year-over-year growth, narrowing losses, and reiterated guidance suggest a more orderly improvement in fundamentals, whereas Sensus Healthcare's sharp revenue contraction and financing-related disruptions introduce greater uncertainty despite its compelling reimbursement catalyst. This assessment reflects observable positioning rather than a definitive forecast, and it is best understood as a probabilistic, data-informed comparison between two speculative small-cap medical device stocks.
How I Use Tickeron’s AI Trading Bots
In my own research process, I often review Tickeron’s Trending AI Robots to see how systematic strategies are positioned in names like these. The page surfaces bots with strong recent performance across thousands of tickers, complete with metrics on style, timeframe, and results. It gives a practical sense of where automated flows may be heading without replacing my own analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SRTS's RSI Oscillator recovers from oversold territory
The RSI Indicator for SRTS moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 29 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 226 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SRTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRTS as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for SRTS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 27 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.228) is normal, around the industry mean (4.204). P/E Ratio (-2.926) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. SRTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of skin cancer treatment products
Industry MedicalNursingServices
Advertisement